Eli Lilly Announces Acquisition of 3 Vaccine Makers in $4 Billion Deal
Lilly is expanding into infectious-disease vaccines as it uses cash from obesity-drug sales to buy early-stage platforms targeting viral and bacterial pathogens.
- On Tuesday, Eli Lilly and Company announced from Indianapolis agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. for up to $3.83 billion in cash, expanding its infectious disease research and development efforts.
- Driven by sales of tirzepatide-based obesity and diabetes drugs Zepbound and Mounjaro, Lilly is returning to infectious disease after seven years, with a 2026 acquisition spree exceeding $20 billion "to aggressively reinvest obesity cash flows to enhance its pipeline," Leerink Partners analyst David Risinger said.
- Vaccine Company, a viral vaccine developer, uses In Vivo Nanoparticle technology for a five-antigen Phase 1-ready Epstein-Barr Virus candidate, while Curevo's Phase 2 amezosvatein shingles vaccine cut fatigue, chills and injection-site pain by more than half.
- Regulatory approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions must be satisfied before the deals close, while Eli Lilly shares climbed 1.36% from $1,065 Friday to $1,079.19 by late trading Tuesday.
- The acquisitions, which Daniel M. Skovronsky, M.D., Ph.D., Lilly's chief scientific and product officer, said "reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," support diversification beyond obesity drugs for a company with market capitalization around $1 trillion.
43 Articles
43 Articles
Eli Lilly, a U.S. pharmaceutical company that has grown rapidly with drugs such as the diabetes and obesity treatment 'Maunzaro,' is acquiring three vaccine developers at once. The total acquisition is estimated to reach up to $3.8 billion (approximately 5.7 trillion won). The acquisition targets include Curevo, a U.S. vaccine developer in which the South Korean pharmaceutical company GC Green Cross holds a stake. This move is interpreted as an …
Lilly Follows Upbeat Trials for Cholesterol Shot with $4B M&A Spree
The Nvidia playbook seems to be just what the doctor ordered for Eli Lilly. Similar to the way the chipmaker powered the artificial intelligence boom, Lilly is parlaying its blockbuster weight-loss drug gold rush into a massive stake in the future of medicine. The latest investments from the pharma giant, announced Tuesday, are three acquisitions meant to boost its infectious disease portfolio: Curevo, LimmaTech Biologic and Vaccine Company, wh…
Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infectious diseases.
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
